---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092005"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2026-08-06T20:11:30+00:00"
generated_at: "2026-08-06T20:15:47.368074+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CVRx Q2 revenue $15.7M (+16% YoY); lowers FY2026 revenue guidance to $58-60M

## Summary
- Net loss $14.0M ($0.53/share) vs $14.7M ($0.57) in Q2 2025; cash $64.6M.
- U.S. revenue $14.8M (+21% YoY) on 466 units; active implanting centers grew to 258.
- Humana issued Medicare Advantage coverage policy for Barostim, effective May 1, 2026.
- FY2026 guidance: total revenue $58-60M, gross margin 86-87%, operating expenses $99-101M.
- Q3 2026 revenue expected between $13.5M and $14.5M; cites sales territory and payer headwinds.

## SEC filing metadata
- accession: 0001104659-26-092005
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2026-08-06T20:11:30+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465926092005/0001104659-26-092005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465926092005/tm2622361d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092005
- JSON: https://secwatch.observer/filing/0001104659-26-092005.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.